Description: Nanosynth Group Plc, together with its subsidiaries, focuses on the synthesis and application of nanoparticles. The company offers nanoparticles for animal food, disease control, healthcare, human nutrition, and advanced materials applications; plant nutrition products; and security and risk management consultancy services, as well as IRIS, an incident management system that enable users to collect and analyze various data in bespoke formats, such as threat risk assessments, audits, and surveys. It also provides anti-viral masks for prevention from COVID-19, and other infectious viral and bacterial diseases. The company was formerly known as Remote Monitored Systems plc and changed its name to Nanosynth Group Plc in August 2021. Nanosynth Group Plc was incorporated in 2014 and is headquartered in London, the United Kingdom
Home Page: www.nanosynthgroup.com
NNN Technical Analysis
27-28 Eastcastle Street
London,
W1W 8DH
United Kingdom
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Mark Duffin B.E., M.B.A. | Group CEO & Director |
| Mr. Peter McNamara B.Sc., F.C.A. | Chief Operating Officer |
| Dr. Gareth WynnVaughan Cave Ph.D. | Chief Scientific Officer & Exec. Director |
| Mr. Andrew John Christian Stedman | CFO & Director |
| Ms. Linda Saleh B.Sc. | HR Director |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5799 |
| Price-to-Sales TTM: | 106.8038 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |